DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer

Journal of Pathology

Volumn 236, Issue 1, 2015, Pages 90-102

  Maglic, Dejan ^a,d   Stovall, Daniel B ^a,e   Cline, J Mark ^a   Fry, Elizabeth A ^a   Mallakin, Ali ^b   Taneja, Pankaj ^a,f   Caudell, David L ^a   Willingham, Mark C ^a   Sui, Guangchao ^a,c   Inoue, Kazushi ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b West Coast Biomedius   (Canada)

^c NORTHEAST FORESTRY UNIVERSITY   (China)

^d HARVARD UNIVERSITY   (United States)

^e North Carolina Wesleyan College   (United States)

^f SHARDA UNIVERSITY   (India)

Author keywords

alternative splicing; Arf; breast cancer; DMP1 (DMP1 and DMP1 ); DMTF1; MMTV; p53

Indexed keywords

D BINDING MYB LIKE PROTEIN 1ALPHA; D BINDING MYB LIKE PROTEIN 1BETA; PROTEIN MYB; UNCLASSIFIED DRUG; DMP1 PROTEIN, HUMAN; DMTF1 PROTEIN, MOUSE; PHOSPHOPROTEIN; SCLEROPROTEIN; TRANSCRIPTION FACTOR;

ADENOSQUAMOUS CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; D BINDING MYB LIKE PROTEIN 1 GENE; GENE LOCUS; GENE VECTOR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ALTERNATIVE RNA SPLICING; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; DISEASE COURSE; FEMALE; GENETICS; MAMMARY GLAND; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; MICE, TRANSGENIC; PHOSPHOPROTEINS; TRANSCRIPTION FACTORS;

EID: 84927695777     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4504     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Mariotto AB, Robin Yabroff K, Shao Y, et al., Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011; 103: 117-128.
3. Taneja P, Maglic D, Kai F, et al., Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol 2010; 4: 15-34.
4. Higgins MJ, Baselga J,. Targeted therapies for breast cancer. J Clin Invest 2011; 121: 3797-3803.
5. Ring A, Dowsett M,. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11: 643-658.
6. Marquette C, Nabell L,. Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol 2012; 13: 263-275.
7. Bleyer A, Welch HG,. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012; 367: 1998-2005.
8. Keyomarsi K, Tucker SL, Buchholz TA, et al., Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1566-1575.
9. Esteva FJ, Hortobagyi GN,. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004; 6: 109-118.
10. Taneja P, Maglic D, Kai F, et al., Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development. Cancer Res 2010; 70: 9084-9094.
11. Maglic D, Zhu S, Fry EA, et al., Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene 2013; 32: 4120-4129.
12. Fry EA, Taneja P, Maglic D, et al., Dmp1α inhibits HER2/neu-induced mammary tumorigenesis. PLoS One 2013; 8: e77870.
13. Inoue K, Roussel MF, Sherr CJ,. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U S A 1999; 96: 3993-3998.
14. Sreeramaneni R, Chaudhry A, McMahon M, et al., Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 2005; 25: 220-232.
15. Frazier DP, Kendig RD, Kai F, et al., Dmp1 physically interacts with p53 and positively regulates p53's stability, nuclear localization, and function. Cancer Res 2012; 72: 1740-1750.
16. Inoue K, Zindy F, Randle DH, et al., Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev 2001; 15: 2934-2939.
17. Mallakin A, Sugiyama T, Taneja P, et al., Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell 2007; 12: 381-394.
18. Inoue K, Wen R, Rehg JE, et al., Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev 2000; 14: 1797-1809.
19. Tschan MP, Fischer KM, Fung VS, et al., Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. J Biol Chem 2003; 278: 42750-42760.
20. Kornblihtt AR, Schor IE, Allo M, et al., Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nature Rev Mol Cell Biol 2013; 14: 153-165.
21. David CJ, Manley JL,. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010; 24: 2343-2364.
22. Cohen-Eliav M, Golan-Gerstl R, Siegfried Z, et al., The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. J Pathol 2013; 229: 630-639.
23. Karni R, de Stanchina E, Lowe SW, et al., The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nature Struct Mol Biol 2007; 14: 185-193.
24. Murray-Zmijewski F, Lane DP, Bourdon JC,. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006; 13: 962-972.
25. Moll UM, Slade N,. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004; 2: 371-386.
26. Miura K, Fujibuchi W, Unno M,. Splice isoforms as therapeutic targets for colorectal cancer. Carcinogenesis 2012; 33: 2311-2319.
27. Mallakin A, Sugiyama T, Kai F, et al., The Arf-inducing transcription factor Dmp1 encodes transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1. Int J Cancer 2010; 126: 1403-1416.
28. Taneja P, Frazier DP, Kendig RD, et al., MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn 2009; 9: 423-440.
29. Ross SR,. Mouse mammary tumor virus molecular biology and oncogenesis. Viruses 2010; 2: 2000-2012.
30. Radaelli E, Arnold A, Papanikolaou A, et al., Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas. Vet Pathol 2009; 46: 736-745.
31. David CJ, Chen M, Assanah M, et al., HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463: 364-368.
32. Uramoto H, Sugio K, Oyama T, et al., Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 2004; 10: 6905-6911.
33. Inoue K, Sherr CJ,. Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol 1998; 18: 1590-1600.
34. Soo K, Tan PH,. Low-grade adenosquamous carcinoma of the breast. J Clin Pathol 2013; 66: 506-511.
35. Pirkmaier A, Dow R, Ganiatsas S, et al., Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma. Oncogene 2003; 22: 8.
36. Wang TC, Cardiff RD, Zukerberg L, et al., Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-671.
37. Merdzhanova G, Gout S, Keramidas M, et al., The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 2010; 29: 5392-5403.
38. Watermann DO, Tang Y, zur Hausen A, et al., Splicing factor Tra2-β1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res 2006; 66: 4774-4780.
39. Xiao R, Sun Y, Ding J-H, et al., Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Mol Cell Biol 2007; 27: 5393-5402.